NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
82.27
+1.47 (+1.82%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close80.80
Open82.29
Bid0.00 x 0
Ask0.00 x 0
Day's Range82.17 - 82.61
52 Week Range72.30 - 94.19
Volume4,003,077
Avg. Volume1,727,026
Market Cap210.938B
Beta0.86
PE Ratio (TTM)24.12
EPS (TTM)3.41
Earnings DateN/A
Forward Dividend & Yield2.98 (3.85%)
Ex-Dividend Date2018-03-06
1y Target Est88.16
Trade prices are not sourced from all markets
  • Novartis won’t raise drug prices in US
    Fox Business Videosyesterday

    Novartis won’t raise drug prices in US

    Fox News Medical A Team’s Dr. Marc Siegel on how Novartis announced that it wouldn’t raise prices on its products in the United States for the rest of 2018.

  • Morgan Stanley gains on earnings; Novartis halts drug price hikes; Texas Instruments CEO steps down; Ford recalls 550K vehicles
    Yahoo Finance Video3 days ago

    Morgan Stanley gains on earnings; Novartis halts drug price hikes; Texas Instruments CEO steps down; Ford recalls 550K vehicles

    Yahoo Finance’s Seana Smith on the stocks making headlines in midday trading Wednesday.

  • Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board
    Yahoo Finance Video3 days ago

    Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board

    Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!

  • MarketWatch8 hours ago

    Pfizer gets FDA approval for drug similar to Amgen's Neupogen

    Pfizer Inc. (pfe) said late Friday it received Food and Drug Administration approval to sell a biotech drug that is similar to Amgen Inc.'s (amgn) Neupogen. Pfizer's product is named Nivestym, which is intended to reduce the likelihood of infections in cancer patients receiving chemotherapy. In a statement, Pfizer said it expects to sell Nivestym at "a significant discount to the current wholesale acquisition cost" of Neupogen.

  • Reuters15 hours ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.

  • Top Research Reports for Microsoft, Novartis & Goldman Sachs
    Zacks15 hours ago

    Top Research Reports for Microsoft, Novartis & Goldman Sachs

    Top Research Reports for Microsoft, Novartis & Goldman Sachs

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks17 hours ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • Reuters17 hours ago

    Swiss, German drugmakers join U.S. price freeze

    Roche, Bayer and Germany's Merck KGaA became the latest drug companies to freeze prices in the United States, amid increased scrutiny by the Trump administration of medicine costs. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis, Pfizer and U.S. drugmaker Merck which had already announced similar moves.

  • TheStreet.com19 hours ago

    Three Key Takeaways From Healthcare Earnings Season

    As the initial wave of healthcare companies unveil quarterly results, here are three takeaways from earnings calls. 1. Drugmakers are rethinking pricing strategies After Pfizer Inc. earlier this month said it would defer price hikes, Novartis AG said Wednesday, July 18, it will not raise prices for the rest of the year.

  • ACCESSWIRE19 hours ago

    Free Post Earnings Research Report: Novartis’ Net Sales Jumped 7%; Non-GAAP EPS Advanced 6%

    LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free earnings report on Novartis AG (NYSE: NVS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NVS. The Company reported its second quarter fiscal 2018 operating and financial results on July 18, 2018. For the second quarter of the fiscal year 2018, Novartis’ net sales were $13.2 billion, up 7% compared to $12.2 billion in Q2 2017, driven by volume growth, mainly in Innovative Medicines.

  • Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion
    Zacksyesterday

    Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion

    Novartis' (NVS) breast cancer drug, Kisqali, gets FDA approval as first-line treatment for pre-, peri- or post-menopausal women with HR+/HER2- advanced breast cancer.

  • Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS
    Bloomberg2 days ago

    Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS

    Novartis AG has launched legal attacks on about two dozen generic-drug makers in a move to protect U.S. sales of its best-selling branded drug.

  • Benzinga2 days ago

    Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...

  • The Wall Street Journal2 days ago

    [$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal

    NV (GLPG.AE) rose on Thursday after the companies said they have reached an agreement worth as much as $1 billion to market an innovative drug. The agreement is for monoclonal antibody MOR106, which is used mainly for the skin condition atopic dermatitis. The deal is exclusive and covers the commercialization of the compound, which was jointly developed by MorphoSys and Galapagos.

  • Reuters2 days ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • Reuters2 days ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • Bloomberg2 days ago

    Novartis to Pay as Much as $1 Billion for Rights to Skin Drug

    Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines. Novartis will pay 95 million euros ($111 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement Thursday. The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.

  • Reuters2 days ago

    Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

    Novartis said on Thursday it will pay 95 million euros to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its ...

  • The Wall Street Journal2 days ago

    [$$] Novartis Won’t Raise U.S. Drug Prices This Year

    Novartis AG won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said Wednesday, days after Pfizer Inc. took a similar step following criticism from President Donald Trump. In an interview, Novartis Chief Executive Vas Narasimhan said the company would evaluate its strategy for 2019 when it has more clarity on the pricing environment. Last week, Pfizer said it would defer some recent drug-price increases, reversing course after Mr. Trump criticized the company for its plans to raise the prices of more than 40 drugs.

  • Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
    Zacks2 days ago

    Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto

    Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.

  • TheStreet.com2 days ago

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • Reuters3 days ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Novartis hints at 2018 outlook hike despite drug price freeze
    Reuters3 days ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Barrons.com3 days ago

    Novartis Earnings: 'A Focused Company Wins,' Says CEO

    Shares of Novartis (NVS) are climbing on Wednesday after the company reported second-quarter earnings. For the full year, Novartis reaffirmed guidance, saying it expects revenue percentage growth of low- to mid-single digits. The report comes after a number of changes at Novartis, including plans to spin off the Alcon eye-care business, the purchase of gene-therapy company AveXis, and the divestiture of its stake in a consumer health-care business joint venture with GlaxoSmithKline (GSK).

  • Stocks mixed; Bernanke, Geithner, and Paulson raise concerns about next financial crisis
    Yahoo Finance3 days ago

    Stocks mixed; Bernanke, Geithner, and Paulson raise concerns about next financial crisis

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.